Biosafety and Biosecurity Challenges Facing Veterinary Diagnostic Laboratories in Lower-Middle Income Countries in Southeast Asia: A Case Study of Thailand

Biosafety and Biosecurity Challenges Facing Veterinary Diagnostic Laboratories in Lower-Middle Income Countries in Southeast Asia: A Case Study of Thailand

Introduction: Global issues over rising and transboundary infectious zoonotic ailments have elevated illness diagnostic calls for, particularly in the veterinary sector. In growing or newly developed nations the place the sector usually works beneath restricted capability, biosafety and biosecurity are unlikely to be high-priority points. A latest improvement program supported by the Biological Threat Reduction Program of the Defense Threat Reduction Agency funded by the US authorities aimed to extend biosafety and biosecurity measures of authorities veterinary diagnostic and analysis laboratories in Thailand.

Objective: The function of this text is to determine biosafety and biosecurity challenges, alternatives, and suggestions.

Methods: Eleven authorities laboratory facilities have been assessed towards the Biosafety in Microbiological and Biomedical Laboratories (BMBLbiosafety degree 2 (BSL-2) necessities guidelines. The BMBL evaluation outcomes have been then mixed with the outcomes of dialogue periods, and the outcomes of pre- and post-test questionnaires carried out throughout biosafety evaluation workshops and self-evaluation experiences utilizing the Food and Agriculture Organization Biosafety Laboratory Mapping Tool of every laboratory heart have been reviewed and summarized.

Results: Despite established nationwide insurance policies on laboratory biosafety and biosecurity, main challenges included (1) harmonization and enforcement of these insurance policies, particularly on the regional degree, and (2) engagement of personnel in implementations of biosafety and biosecurity measures.

Conclusion: Consistent biosafety coverage and allotted assets along with common coaching are required to develop sustainable biosafety and biosecurity on the nationwide degree. Collaboration between regional nations, worldwide organizations, and donors is crucial for bettering biosafety and biosecurity on a world scale by means of setting regional priorities, enacting regulatory requirements, and offering technical and monetary help.

 Biosafety and Biosecurity Challenges Facing Veterinary Diagnostic Laboratories in Lower-Middle Income Countries in Southeast Asia: A Case Study of Thailand
Biosafety and Biosecurity Challenges Facing Veterinary Diagnostic Laboratories in Lower-Middle Income Countries in Southeast Asia: A Case Study of Thailand

Lab-Scale Production of Recombinant Adeno-Associated Viruses (AAV) for Expression of Optogenetic Elements

Optogenetics, that’s, the use of photoswitchable/-activatable moieties to exactly management or monitor the exercise of cells and genes at unprecedented spatiotemporal decision, holds great promise for a wide selection of purposes in elementary and scientific analysis. To absolutely notice and harness this potential, the supply of gene switch autos (“vectors”) which can be simply produced and that permit to ship the important parts to desired goal cells in an environment friendly method is vital.

For in vivo purposes, it’s, furthermore, necessary that these vectors exhibit a excessive diploma of cell specificity in order to scale back the danger of adversarial uncomfortable side effects in off-targets and to reduce manufacturing prices. Here, we describe a set of fundamental protocols for the cloning, manufacturing, purification, and high quality management of a selected vector that may fulfill all these necessities, that’s, recombinant adeno-associated viruses (AAV).

The latter are very engaging owing to their apathogenicity, their compatibility with the bottom biosafety degree 1 circumstances, their incidence in a number of pure variants with distinct properties, and their distinctive amenability to engineering of the viral capsid and genome.

Human FLT-1/VEGFR-1 Control/blocking peptide #1

FLT11-P 100 ug
EUR 196.8

VEGFR binding peptide KH / QKRKRKKSRKKH

007-58 100 μg
EUR 158.76

VEGFR binding peptide IVLS / RKRKRKKSRYIVLS

007-59 100 μg
EUR 171.72

Human FLT-4/VEGFR-3 control/blocking peptide #2

FLT42-P 100 ug
EUR 196.8

Mouse FLT-4/VEGFR-3 Control/blocking peptide #1

FLT41-P 100 ug
EUR 196.8

Rabbit anti VEGFR-1/Flt-1 (human)

102-PA20S 100ug
EUR 240

Mouse anti VEGFR-1/Flt-1 (#EWC) (human)

101-M24 100ug
EUR 297.6

Mouse anti VEGFR-1/Flt-1 (#EIC) (human)

101-M26 100ug
EUR 297.6

Mouse anti VEGFR-1/Flt-1 (#EWF) (human)

101-M28 100ug
EUR 297.6

Mouse anti VEGFR-1/Flt-1 (#EWI) (human)

101-M30 100ug
EUR 297.6

Mouse anti VEGFR-3/Flt-4 (#1) (human)

101-M36 100ug
EUR 297.6

Mouse Anti-Human VEGFR-1/Flt-1

MBS690002-01mg 0.1mg
EUR 430

Mouse Anti-Human VEGFR-1/Flt-1

MBS690002-5x01mg 5x0.1mg
EUR 1645

Mouse Anti-Human VEGFR-1/Flt-1

MBS690109-005mg 0.05mg
EUR 450

Mouse Anti-Human VEGFR-1/Flt-1

MBS690109-5x005mg 5x0.05mg
EUR 1725

Mouse Anti-Human VEGFR-1/Flt-1

MBS690355-01mg 0.1mg
EUR 450

Mouse Anti-Human VEGFR-1/Flt-1

MBS690355-5x01mg 5x0.1mg
EUR 1725

Mouse Anti-Human VEGFR-1/Flt-1

MBS690361-01mg 0.1mg
EUR 450

Mouse Anti-Human VEGFR-1/Flt-1

MBS690361-5x01mg 5x0.1mg
EUR 1725

Mouse Anti-Human VEGFR-1/Flt-1

MBS690384-005mg 0.05mg
EUR 430

Mouse Anti-Human VEGFR-1/Flt-1

MBS690384-5x005mg 5x0.05mg
EUR 1645

Mouse Anti-Human VEGFR-1/Flt-1

MBS690483-005mg 0.05mg
EUR 430

Mouse Anti-Human VEGFR-1/Flt-1

MBS690483-5x005mg 5x0.05mg
EUR 1645

Mouse Anti-Human VEGFR-1/Flt-1

MBS690832-01mg 0.1mg
EUR 430

Mouse Anti-Human VEGFR-1/Flt-1

MBS690832-5x01mg 5x0.1mg
EUR 1645

Anti-Human VEGFR-1/Flt-1 Antibody

101-MBi24 50 µg
EUR 246.75
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Anti-Human VEGFR-1/Flt-1 Antibody

101-MBi30 50 µg
EUR 189
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Anti-Human VEGFR-1/Flt-1 Antibody

102-PA20 200 µg
EUR 173.25
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Anti-Human VEGFR-1/Flt-1 Antibody

102-PABi20 50 µg
EUR 157.5
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

anti- VEGFR-1/FLT-1 antibody

FNab09393 100µg
EUR 606.3
Description: Antibody raised against VEGFR-1/FLT-1

Mouse anti VEGFR-1/Flt-1-Biotin (#EWF) (human)

101-MBi28 50ug
EUR 297.6

Human VEGFR-1/Flt-1 (D5), soluble

MBS691664-002mg 0.02mg
EUR 380

Human VEGFR-1/Flt-1 (D5), soluble

MBS691664-5x002mg 5x0.02mg
EUR 1410

Human VEGFR-1/Flt-1 (D5), soluble

MBS691669-0005mg 0.005mg
EUR 265

Human VEGFR-1/Flt-1 (D5), soluble

MBS691669-5x0005mg 5x0.005mg
EUR 890

Human VEGFR-1/Flt-1 (D3), soluble

MBS691717-002mg 0.02mg
EUR 450

Human VEGFR-1/Flt-1 (D3), soluble

MBS691717-5x002mg 5x0.02mg
EUR 1725

Human VEGFR-1/Flt-1 (D4), soluble

MBS691847-0005mg 0.005mg
EUR 310

Human VEGFR-1/Flt-1 (D4), soluble

MBS691847-5x0005mg 5x0.005mg
EUR 1110

Human VEGFR-1/Flt-1 (D3), soluble

MBS692000-0005mg 0.005mg
EUR 310

Human VEGFR-1/Flt-1 (D3), soluble

MBS692000-5x0005mg 5x0.005mg
EUR 1110

Human VEGFR-1/Flt-1 (D4), soluble

MBS692119-002mg 0.02mg
EUR 450

Human VEGFR-1/Flt-1 (D4), soluble

MBS692119-5x002mg 5x0.02mg
EUR 1725

Human VEGFR-1/Flt-1 (native), soluble

MBS691505-0005mg 0.005mg
EUR 265

Human VEGFR-1/Flt-1 (native), soluble

MBS691505-5x0005mg 5x0.005mg
EUR 890

Human VEGFR-1/Flt-1 (native), soluble

MBS691991-002mg 0.02mg
EUR 380

Human VEGFR-1/Flt-1 (native), soluble

MBS691991-5x002mg 5x0.02mg
EUR 1410

Mouse anti VEGFR-3/Flt-4-Biotin (#1) (human)

101-MBi36 50ug
EUR 297.6

VEGFR-1 / FLT-1 Antibody

abx239393-100ug 100 ug
EUR 577.2

VEGFR-1/FLT-1 antibody

E39-09393 100ug/100ul
EUR 225
Description: Available in various conjugation types.

VEGFR-1/FLT-1 antibody

CAF50629-100ug 100ug
EUR 312

Anti-Mouse VEGFR-1/Flt-1 Antibody

103-M31 100 µg
EUR 399
Description: Vascular Endothelial Growth Factor (VEGF or VEGF-A) family members are major mediators of vasculogenesis and angiogenesis. Specifically, biological activities attributed to VEGFs include: mitogenic activity on endothelial cells, increased permeability of endothelial cells to proteins, stimulation of monocyte migration across endothelial cells and angiogenic activity. Three VEGF family receptors have been described: Flt-1 (fms-like tyrosine kinase) also known as VEGF R1, KDR (kinase-insert domain-containing receptor) also known as Flk-1 and VEGF R2, and Flt-4 also known as VEGF R3. The three receptors contain seven extracellular immunoglobulin-like domains and share substantial sequence homology. In addition, neuropilin-1, a neuronal receptor, also acts as a co-receptor for VEGF when expressed on vascular endothelial cells, endothelial cell progenitors and monocytes. VEGF R1 is expressed primarily on endothelial cells but is also found on human peripheral blood monocytes. Through its endothelial mitogenic and hyperpermeability activities, VEGF influences a variety of immune functions related to wound healing and blood protein traffic across endothelial barriers.

Recombinant Human FLT-1/VEGFR-1 Protein

RP01137 50μg
EUR 308.75

Recombinant Human FLT-1/VEGFR-1 Protein

RP02099 100μg
EUR 205.47

Human VEGFR-1/Flt-1 (D3)-His, soluble

MBS692528-005mg 0.05mg
EUR 725

Human VEGFR-1/Flt-1 (D3)-His, soluble

MBS692528-5x005mg 5x0.05mg
EUR 2965

Rabbit anti VEGFR-3/Flt-4 (human)

102-PA22AG 50ug
EUR 240

Rabbit anti VEGFR-3/Flt-4 (human)

102-PA22S 100ug
EUR 240

Anti-Human VEGFR-3/FLT-4 (#1) Antibody

MBS4158541-01mg 0.1mg
EUR 920

Anti-Human VEGFR-3/FLT-4 (#1) Antibody

MBS4158541-5x01mg 5x0.1mg
EUR 3880

Human VEGFR-1/Flt-1(D7)-Fc Chimera, soluble

MBS691483-005mg 0.05mg
EUR 395

Human VEGFR-1/Flt-1(D7)-Fc Chimera, soluble

MBS691483-5x005mg 5x0.05mg
EUR 1490

Human VEGFR-1/Flt-1(D7)-Fc Chimera, soluble

MBS691782-001mg 0.01mg
EUR 245

Human VEGFR-1/Flt-1(D7)-Fc Chimera, soluble

MBS691782-5x001mg 5x0.01mg
EUR 805

Active Recombinant Human FLT-1/VEGFR-1 Protein

RP01188 5 μg
EUR 32.5

Biotinylated Recombinant Human FLT-1/VEGFR-1 Protein

RP02100 500μg
EUR 2843.75

Anti-Human VEGFR-l/Flt-1 (#EWC) Antibody

MBS4158536-01mg 0.1mg
EUR 920

Anti-Human VEGFR-l/Flt-1 (#EWC) Antibody

MBS4158536-5x01mg 5x0.1mg
EUR 3880

Anti-Human VEGFR-l/Flt-1 (#EIC) Antibody

MBS4158537-01mg 0.1mg
EUR 920

Anti-Human VEGFR-l/Flt-1 (#EIC) Antibody

MBS4158537-5x01mg 5x0.1mg
EUR 3880

Anti-Human VEGFR-l/Flt-1 (#EWF) Antibody

MBS4158538-01mg 0.1mg
EUR 920

Anti-Human VEGFR-l/Flt-1 (#EWF) Antibody

MBS4158538-5x01mg 5x0.1mg
EUR 3880

Human VEGFR-1/Flt-1 (D5), soluble Recombinant Protein

S01-011 5 µg
EUR 73.5
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-5 (sVEGFR-1(D5)) is a 70 kDa protein. The baculovirus generated, recombinant human sVEGFR-1 is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 5 extracellular domains, which contain all the information necessary for high affinity ligand binding. The receptor monomers have a mass of approximately 70 kDa. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.

Human VEGFR-1/Flt-1 (D5), soluble Recombinant Protein

S01-012 20 µg
EUR 157.5
Description: Recombinat human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-5 (sVEGFR-1(D5)) is a 70 kDa protein containing amino acid residues. The baculovirus generated, recombinant human sVEGFR-1 is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 5 extracellular domains, which contain all the information necessary for high affinity ligand binding. The receptor monomers have a mass of approximately 70 kDa. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVE supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.

Human VEGFR-1/Flt-1 (D4), soluble Recombinant Protein

S01-013 5 µg
EUR 103.95
Description: Recombinant Human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-4 (sVEGFR-1(D4)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 4 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 55 kDa containing 457 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.

Human VEGFR-1/Flt-1 (D4), soluble Recombinant Protein

S01-014 20 µg
EUR 199.5
Description: Recombinant Human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-4 (sVEGFR-1(D4)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 4 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 55 kDa containing 457 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.

Human VEGFR-1/Flt-1 (D3), soluble Recombinant Protein

S01-015 5 µg
EUR 103.95
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-3 (sVEGFR-1(D3)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 3 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 45 kDa containing 352 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.

Human VEGFR-1/Flt-1 (D3), soluble Recombinant Protein

S01-016 20 µg
EUR 199.5
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-3 (sVEGFR-1(D3)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 3 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 45 kDa containing 352 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.

Human VEGFR-1/Flt-1 (native), soluble Recombinant Protein

S01-009 5 µg
EUR 73.5
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) is the naturally occurring form and was cloned from total RNA of human umbilical vein endothelial cells. The recombinant mature sVEGFR-1 is a glycosylated monomeric protein with a mass of approximately 96 kDa. The soluble receptor precursor protein consists of the first 6 extracellular domains (Met1-His688) containing the unique 31 amino acids residues at the C-terminus. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly, a naturally occurring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.

Human VEGFR-1/Flt-1 (native), soluble Recombinant Protein

S01-010 20 µg
EUR 157.5
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) is the naturally occurring form and was cloned from total RNA of human umbilical vein endothelial cells. The recombinant mature sVEGFR-1 is a glycosylated monomeric protein with a mass of approximately 96 kDa. The soluble receptor protein consists of the first 6 extracellular domains (Met1-His688) containing the unique 31 amino acids residues at the C-terminus. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly, a naturally occurring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis binding VEGF with the same affinity as the full-length receptor.

Anti-Mouse VEGFR-2/Flk-1 (Peptide), soluble Antibody

103-PA19S 100 µg
EUR 126
Description: The antibody recognizes solely the endogenous soluble form of mouse vascular endothelial growth factor receptor 2, alos known as CD309, VEGFR2, KDR, protein tyrosine kinase receptor flk-1, and fetal liver kinase-1. The endogenous soluble mouse esFlk-1 generated by alternative splicing consists of the first 6 Ig-like loops followed by the unique C-terminal end: GMEASLGDRIAMP. Flk-1 is a member of the tyrosine protein kinase family, sub-family CSF-1/PDGF, that contains a single pass transmembrane receptor with a protein kinase domain and seven immunoglobulin-like domains in the extracellular region. Flk-1 is expressed at high levels in adult heart, lung, kidney, brain, and skeletal muscle; other tissues express at lower levels. Flk-1 is a receptor for VEGF-A or fully processed VEGF-C; ligand binding plays a key role in vascular development and vascular permeability.

Rabbit Anti-human FLT-1/VEGFR-1 IgG #1, aff pure

FLT11-A 100 ul
EUR 578.4

Rabbit Anti-Mouse VEGFR-2 Flk-1 (Peptide), soluble

103-PA19 100ug
EUR 240

Anti-Inflammatory Peptide 1

004-01 200 μg
EUR 27

Anti-Hu/Mo VEGFR-1/Flt-1, Antagonistic Antibody

mV1004.1m-h-m 100 µg
EUR 645.75
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The antibody will bind near the ligand binding site of the receptor and has antagonistic activity by blocking the binding of natural ligands.

Defensin I / Human Neutrophil Peptide-1 (HNP-1) (Human)

072-17 100 μg
EUR 370.44

RFamide-Related Peptide 1 (RFRP-1) (Human)

048-42 500 μg
EUR 177.12

Human VEGFR-1/Flt-1 (D3)-His, soluble Recombinant Protein

S01-080 50 µg
EUR 378
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-3 (sVEGFR-1(D3)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 3 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 45 kDa containing 352 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0001 1.0mg
EUR 691.2
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0005 5.0mg
EUR 2648.4
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

Human VEGFR-3/FLT-4, soluble

MBS691602-001mg 0.01mg
EUR 310

Human VEGFR-3/FLT-4, soluble

MBS691602-5x001mg 5x0.01mg
EUR 1110

Human VEGFR-3/FLT-4, soluble

MBS691970-005mg 0.05mg
EUR 465

Human VEGFR-3/FLT-4, soluble

MBS691970-5x005mg 5x0.05mg
EUR 1805

Human VEGFR-3/FLT-4, soluble

MBS692181-0005mg 0.005mg
EUR 250

Human VEGFR-3/FLT-4, soluble

MBS692181-5x0005mg 5x0.005mg
EUR 835

Anti-Human VEGFR-l/Flt-1 (#EWF) Biotin Antibody

MBS4158553-005mg 0.05mg
EUR 920

Anti-Human VEGFR-l/Flt-1 (#EWF) Biotin Antibody

MBS4158553-5x005mg 5x0.05mg
EUR 3880

Anti-Human VEGFR-3/FLT-4 (CL 1) Biotin Antibody

MBS4158555-005mg 0.05mg
EUR 920

Anti-Human VEGFR-3/FLT-4 (CL 1) Biotin Antibody

MBS4158555-5x005mg 5x0.05mg
EUR 3880

[Tyr0]-RFamide-Related Peptide 1 (RFRP-1) (Human)

048-43 200 μg
EUR 177.12

Mouse Anti-Human VEGFR-3/FLT-4

MBS690017-01mg 0.1mg
EUR 450

Mouse Anti-Human VEGFR-3/FLT-4

MBS690017-5x01mg 5x0.1mg
EUR 1725

Mouse Anti-Human VEGFR-3/FLT-4

MBS690153-01mg 0.1mg
EUR 450

Mouse Anti-Human VEGFR-3/FLT-4

MBS690153-5x01mg 5x0.1mg
EUR 1725

Mouse Anti-Human VEGFR-3/FLT-4

MBS690532-005mg 0.05mg
EUR 450

Mouse Anti-Human VEGFR-3/FLT-4

MBS690532-5x005mg 5x0.05mg
EUR 1725

Anti-Human VEGFR-3/FLT-4 Antibody

101-M37 100 µg
EUR 199.5
Description: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.

Anti-Human VEGFR-3/FLT-4 Antibody

101-M38 100 µg
EUR 399
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (Flt1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides which remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

Anti-Human VEGFR-3/FLT-4 Antibody

101-M870 100 µg
EUR 399
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (Flt1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides which remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

Anti-Human VEGFR-3/FLT-4 Antibody

102-PA22 200 µg
EUR 147
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

Anti-Human VEGFR-3/FLT-4 Antibody

102-PABi22 50 µg
EUR 157.5
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

Rabbit Anti-Human VEGFR-2/KDR (Peptide), soluble

102-PA19 100ug
EUR 240

Nesfatin-1-Like Peptide (NLP) (Human)

009-83 100 μg
EUR 469.8

Peptide YY (PYY) (1-36)-Gly (Human)

059-07 100 μg
EUR 295.92

Anti-Human VEGFR-2/KDR (Peptide), soluble Antibody

102-PA19S 100 µg
EUR 126
Description: VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

Mouse Monoclonal Anti-human FLT-1/VEGFR-1 IgG, aff pure

FLT12-M 100 ug
EUR 578.4

Mouse Monoclonal Anti-human FLT-1/VEGFR-1 IgG, aff pure

FLT14-M 100 ug
EUR 578.4

GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human)

029-03 500 μg
EUR 114.48

GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human)

029-04 100 μg
EUR 114.48

GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human)

029-05 20 μg
EUR 267.84

TCAP-1 / Teneurin C-terminal Associated Peptide-1 (Human)

020-16 100 μg
EUR 317.52

SHLP1 / Small Humanin-Like Peptide 1 (Human)

018-75 100 μg
EUR 263.52

RFamide-Related Peptide 1 (RFRP-1) (Human) - FAM Labeled

FG-048-42A 1 nmol
EUR 336.96

Gastrin Releasing Peptide (GRP) (1-16) (Human)

027-08 1 mg
EUR 177.12

Gastrin Releasing Peptide (GRP) (1-17) (Human)

027-42 200 μg
EUR 189

prepro-Endothelin-1 (ET-1) Like Peptide (109-130) amide (Human)

023-11 100 μg
EUR 355.32

Human VEGFR-1/Flt-1(D7)-Fc Chimera, soluble Recombinant Protein

SFC-005 10 µg
EUR 57.75
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1(D7)) was fused with the Fc part of human IgG1. The recombinant mature sVEGFR-1(D7)/Fc is a disulfide-linked homodimeric protein. The sVEGFR-1(D7)/Fc monomers have a mass of approximately 130 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signalling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin.

Human VEGFR-1/Flt-1(D7)-Fc Chimera, soluble Recombinant Protein

SFC-006 50 µg
EUR 168
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1(D7)) was fused with the Fc part of human IgG1. The recombinant mature sVEGFR-1(D7)/Fc is a disulfide-linked homodimeric protein. The sVEGFR-1(D7)/Fc monomers have a mass of approximately 130 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signalling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin.

Human VEGFR-3/FLT-4 ELISA (total)

MBS691467-0096mg 0.096mg
EUR 815

Human VEGFR-3/FLT-4 ELISA (total)

MBS691467-5x0096mg 5x0.096mg
EUR 3625

RFamide-Related Peptide 1 (RFRP-1) (Human) - Rhodamine Labeled

FR-048-42 1 nmol
EUR 336.96

Mouse FLK-1/VEGFR-2 control/blocking peptide # 1

FLK11-P 100 ug
EUR 196.8

Human VEGFR-3 / Flt-4 GENLISA ELISA

KBH0215 1 x 96 wells
EUR 286

Neuroendocrine Regulatory Peptide 1 (NERP-1) / prepro-VGF (281-306) (Human) - Antibody

H-076-89 100 μl
EUR 336.96

Nesfatin-1-Like Peptide(NLP) (Human) - RIA Kit

RK-009-83 125 tubes
EUR 980.64

Bone Forming Peptide 1 (BFP-1) (Human, Rat, Mouse, Bovine, Feline)

080-57 100ug
EUR 196.56

Recombinant Human VEGFR-3/FLT-4 Protein

RP01797 100μg
EUR 42.51

[Tyr0]-RFamide-Related Peptide 1 (RFRP-1) (Human) - I-125 Labeled

T-048-43 10 μCi
EUR 1145.88

[Biotinyl-Gln1]-TCAP-1 / Teneurin C-terminal Associated Peptide-1 (Human)

B-020-16 20 μg
EUR 336.96

Rat Anti-Mouse VEGFR-3/FLT-4

MBS690799-01mg 0.1mg
EUR 450

Rat Anti-Mouse VEGFR-3/FLT-4

MBS690799-5x01mg 5x0.1mg
EUR 1725

Neuroendocrine Regulatory Peptide 1 (NERP-1) / prepro-VGF (281-306) (Human)

076-89 100 μg
EUR 214.92

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (AP)

MBS6443139-01mL 0.1mL
EUR 950

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (AP)

MBS6443139-5x01mL 5x0.1mL
EUR 4120

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (APC)

MBS6443140-01mL 0.1mL
EUR 950

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (APC)

MBS6443140-5x01mL 5x0.1mL
EUR 4120

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (HRP)

MBS6443143-01mL 0.1mL
EUR 950

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (HRP)

MBS6443143-5x01mL 5x0.1mL
EUR 4120

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (PE)

MBS6443149-01mL 0.1mL
EUR 950

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (PE)

MBS6443149-5x01mL 5x0.1mL
EUR 4120

Rabbit Anti-Mouse FLT-1/VEGFR-1 (279-299aa) IgG, aff pure

FLT15-A 100 ul
EUR 578.4

Anti-Mouse VEGFR-3/FLT-4 Antibody

103-M36 100 µg
EUR 246.75
Description: VEGFR-3, also known as FLT4, is a member of the Tyr protein kinase family. The extracellular portion of VEGFR-3 contains 7 immunoglobulin (Ig)-like domains and the cytoplasmic portion contains a protein kinase domain. FLT4 regulates angiogenesis and lymphangiogenesis, its ligands are VEGF-C and D and its binding is mediated by the 2nd and 3rd Ig-like domains of FLT4. During fetal development VEGFR-3 is expressed on endothelial cells, however, in the adult mice, the vascular endothelial cells lose VEGFR-3 expression, but the lymphatic endothelium expresses it constitutively. In addition, VEGFR-3 expression can be induced in tumors with active angiogenesis.

Anti-Mouse VEGFR-3/FLT-4 Antibody

103-M38 100 µg
EUR 399
Description: Receptor tyrosine kinase VEGFR-3, also known as Flt-4, together with VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remaining linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (FITC)

MBS6443142-01mL 0.1mL
EUR 950

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (FITC)

MBS6443142-5x01mL 5x0.1mL
EUR 4120

VEGFR-3/Flt-4

JP27779 96
EUR 611

VEGFR-3/FLT-4

MBS692733-01mg 0.1mg
EUR 725

VEGFR-3/FLT-4

MBS692733-5x01mg 5x0.1mg
EUR 2965

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (Biotin)

MBS6443141-01mL 0.1mL
EUR 950

VEGFR1 (Vascular Endothelial Growth Factor Receptor 1, FLT, FLT-1, VEGFR1, VEGFR-1) (Biotin)

MBS6443141-5x01mL 5x0.1mL
EUR 4120

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (AP)

MBS6417421-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (AP)

MBS6417421-5x01mL 5x0.1mL
EUR 4120

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (APC)

MBS6417422-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (APC)

MBS6417422-5x01mL 5x0.1mL
EUR 4120

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (HRP)

MBS6417425-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (HRP)

MBS6417425-5x01mL 5x0.1mL
EUR 4120

The particular procedures reported right here complement various protocols for AAV manufacturing described by others and us earlier than, and, collectively, ought to allow any laboratory to generate these vectors on a small-to-medium scale for ex vivo or in vivo expression of optogenetic parts.

Leave A Comment